「スタチンと併用して25%のリスク低減」
グループ内のSNS?で情報を得ました。パクリですけど忘備録として。
https://investor.amarincorp.com/news-releases/news-release-details/reduce-ittm-cardiovascular-outcomes-study-vascepar-icosapent
2018/9/28のプレス発表のようです。結論は以下。
Key topline results include:
Efficacy: Approximately 25% relative risk reduction, demonstrated to a high degree of statistical significance (p<0.001), in the primary endpoint composite of the first occurrence of MACE, including cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization. This result was supported by robust demonstrations of efficacy across multiple secondary endpoints.
Safety: Vascepa was well tolerated with a safety profile consistent with clinical experience associated with omega-3 fatty acids and current FDA-approved labeling. The proportions of patients experiencing adverse events and serious adverse events in REDUCE-IT were similar between the active and placebo treatment groups. Median follow-up time in REDUCE-IT was 4.9 years.
AHAで発表のようですね。今年のAHAはシカゴで11月10-12日。
first occurrence of MACEでのイベントだから一次予防も含むのかな?
これはω-3に追い風ですね。
でもTG:150-499の群ですね。メタボ群に限ってか…
で、コメントの一部でおもしろい記載が
「Considered against the backdrop of multiple unsuccessful cardiovascular outcomes studies of earlier generation drug therapies・・・」
バックドロップて。。。背後から不意打ちをカマすイメージでしたが、調べたら、
backdrop
【名】
〔劇場の〕背景幕◆【同】backcloth
〔景色などの〕背景
〔出来事などの〕背景、状況
〔プロレスの〕バックドロップ◆日本のプロレスの技。◆
うん、背景ね。
お伊勢参り、小学校の修学旅行以来です。 |